CRISPR in 2026: The Gene-Editing Breakthroughs Actually Changing Medicine

In December 2023, the US Food and Drug Administration approved Casgevy, the first medicine in history that works by editing a patient's genome with CRISPR. The treatment, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, was approved for sickle cell disease, with a separate approval for transfusion-dependent beta thalassemia following weeks later. Twelve years after Jennifer Doudna and Emmanuelle Charpentier published the foundational CRISPR-Cas9 paper that earned them the 2020 Nobel Prize in Chemistry, gene editing had reached the clinic.

Two and a half years later, the picture in April 2026 is more complicated than the celebratory press releases suggested. The science has continued to advance, in some cases astonishingly fast. The clinical trial pipeline has matured. New techniques like prime editing have moved from journal papers to active human trials. And yet the actual rollout of approved therapies has been brutally slow, the prices have been higher than even the pessimists predicted, and the gap between what gene editing can do and what it actually does for patients is wider than any other transformative medicine in living memory.

This is what has happened, what is working, and what the field is still struggling to solve.

Casgevy: a cure that almost no one is getting

Casgevy works. The clinical data is overwhelming. In Vertex's pivotal trials and the post-marketing studies that have continued through 2025 and into 2026, more than 95% of treated sickle cell patients have remained free of the vaso-occlusive crises that previously defined their lives. Many have come off pain medication for the first time since childhood. The data for beta thalassemia is similarly striking; nearly all treated patients have become transfusion-independent.

The catch is that, as of early 2026, only a few hundred patients worldwide have actually received the treatment. Vertex disclosed in its February 2026 earnings call that approximately 470 patients had been infused with Casgevy globally, against an addressable population in the US alone of roughly 100,000 sickle cell patients with severe disease.

The reasons are not scientific. Casgevy costs $2.2 million per patient in the US, and the actual delivered cost — including the long hospitalisation, the conditioning chemotherapy, and the supportive care required — pushes the total economic burden close to $3 million per patient. Insurance coverage has been spotty; Medicaid, which covers a disproportionate share of US sickle cell patients, has been slow to negotiate the outcomes-based contracts that Vertex prefers. Outside the US, the rollout has been even slower; the UK's NICE approved Casgevy in 2024 but the NHS budget for cell and gene therapies has been a recurring point of tension with the Treasury.

There is also the operational problem. Casgevy requires the patient's own bone marrow stem cells to be harvested, modified at a specialised facility, and reinfused after the patient has undergone myeloablative chemotherapy to destroy their existing bone marrow. The procedure ties up a hospital bed for weeks and requires expertise that exists at perhaps fifty centres globally. Even if the price problem were solved tomorrow, the supply of qualified treatment centres would not allow more than a few thousand patients per year.

This is the central tension of the CRISPR therapeutics era: the science is mature enough to cure disease, and the healthcare system is not mature enough to deliver the cure.

Verve and the in-vivo revolution

The treatments that have a chance of changing this are the ones that do not require the elaborate ex-vivo cell-extraction-and-reinfusion process that Casgevy uses. The leading example is Verve Therapeutics, which has been running trials of VERVE-101 (and now its successor VERVE-102) for hypercholesterolemia.

The pitch is straightforward and audacious. Atherosclerotic cardiovascular disease is the leading cause of death in the developed world. The PCSK9 gene, when reduced in expression, lowers LDL cholesterol dramatically; the existing class of PCSK9 inhibitor antibodies has been validated to reduce cardiovascular events. Verve's approach is to use base editing to make a single change to the PCSK9 gene in liver cells, in vivo, after a single intravenous infusion. The intended effect is permanent: one treatment, lifelong cholesterol reduction.

The first-in-human data, published in mid-2024 and updated through 2025, demonstrated proof of concept. Patients showed sustained reductions in LDL cholesterol after a single dose, with the effect persisting through the longest follow-up periods reported. The initial VERVE-101 product was discontinued in early 2025 after one patient experienced a transient liver enzyme elevation that the FDA and the company agreed required pausing the trial. VERVE-102, with an improved lipid nanoparticle delivery system, entered Phase 2 trials in late 2025 and the early data has been clean.

If VERVE-102 succeeds in the larger trials that are expected to read out in late 2026 and 2027, it would be the first true single-shot in-vivo gene editing therapy for a common chronic disease. The implications are enormous. The same delivery platform could plausibly be aimed at any liver-expressed gene; the same approach, with different delivery, could in time reach other tissues. The treatment cost, while not yet announced, would be far lower than Casgevy because no ex-vivo cell processing is required.

Eli Lilly's $13.1 billion acquisition of Verve, completed in October 2025, was the clearest signal that the major pharmaceutical industry now believes in vivo gene editing is real.

Cancer applications and the CAR-T enhancement story

CRISPR has been used in cancer immunotherapy for years, primarily as a way to enhance CAR-T cell therapies. The original CAR-T treatments approved in 2017 used viral vectors to insert a chimeric antigen receptor into a patient's T cells, but the approach left several aspects of the cell unmodified. CRISPR allows cancer immunologists to do more: knock out genes that limit T-cell persistence, modify cells to evade rejection in allogeneic (off-the-shelf) products, and stack multiple modifications to create more capable therapeutic cells.

Caribou Biosciences and Allogene have both run trials of allogeneic CAR-T products in 2024 and 2025, with mixed results. Caribou's CB-010 for B-cell lymphoma showed promising early activity but durability has been a recurring concern. Allogene's ALLO-715 for multiple myeloma has had more consistent data. Neither has yet been approved, and the field remains open.

The newer wave of cancer applications uses CRISPR to enhance T-cell receptor (TCR) therapies for solid tumours, which have been the great unsolved problem of cancer immunology. Several academic centres, including the University of Pennsylvania and Memorial Sloan Kettering, have run small trials of TCR-edited cells with encouraging early results. None of this is approved medicine yet, and none of it will be approved before 2027 at the earliest.

Prime editing comes of age

The most important technical development of the last two years is the maturation of prime editing. Where the original CRISPR-Cas9 technique cuts DNA and relies on the cell's repair machinery to make changes, prime editing — developed in David Liu's lab at the Broad Institute and commercialised through Prime Medicine and Beam Therapeutics — uses a more sophisticated molecular machine that can write specific changes into the genome without making double-strand breaks. The advantage is precision: prime editing can in principle correct any of the small mutations that cause monogenic disease, with much less risk of unintended modifications than first-generation CRISPR.

Prime Medicine entered Phase 1/2 trials of PM359 for chronic granulomatous disease in 2024, with the first patient dosed in late 2024 and additional patients dosed through 2025. The early data, presented at the American Society of Hematology meeting in December 2025, showed that the treatment had successfully edited target cells with no detectable off-target effects, although clinical efficacy data is still maturing. Beam Therapeutics' base editing programmes — distinct from but related to prime editing — have advanced in sickle cell disease and other indications, with the company's BEAM-101 trial showing preliminary results comparable to Casgevy but with a different editing approach.

The honest assessment is that prime and base editing remain earlier in clinical development than Cas9-based approaches. The first prime-editing approval is unlikely before 2028. But the technology is now demonstrably working in humans, and that is a far more important milestone than the field had reached two years ago.

The off-target problem and the long shadow of risk

Off-target editing — the worry that CRISPR will modify genes other than the intended target — was the dominant scientific concern of the early gene-editing era, and it has not gone away. Casgevy's clinical data has been reassuring on this point; the BCL11A enhancer that Casgevy targets is well-characterised and the off-target activity in the relevant cell types is below the detection threshold of current sequencing methods.

The harder cases are the in vivo treatments where the editing happens in tissues that cannot be easily sampled and monitored over years. Verve has been transparent about the off-target analysis it performs on circulating cells, but the long-term safety profile of permanent edits to liver cells in millions of patients is not something the trials can fully establish. The field will be living with that uncertainty for years.

The other recurring concern is delivery. Lipid nanoparticles, which Verve uses, have a known affinity for liver cells but reach other tissues with much lower efficiency. Adeno-associated viral vectors, which dominate the gene-therapy field, can target a wider range of tissues but trigger immune responses that can preclude repeat dosing. The next generation of delivery technologies — engineered virus-like particles, targeted nanoparticles, and direct conjugates — is in active development but not yet clinically validated at scale.

What the next two years will determine

The Casgevy experience has shaped the field's expectations in a useful way. The medical community now understands that approving a gene-editing therapy is not the end of the story; it is the beginning of a much harder operational, financial, and access problem. The next wave of approvals will be tested against this reality, and the therapies that succeed will be the ones that have figured out how to be delivered, paid for, and scaled, not just the ones with the best clinical data.

What is unambiguously true in April 2026 is that gene editing has crossed the line from a technology that might cure disease to a technology that does cure disease. The challenge now is for the rest of the system — payers, hospitals, regulators, and the companies themselves — to catch up to what the science has made possible. That is a problem of will and organisation, not of biology, and it is the obstacle that will determine whether CRISPR's first generation reaches the people who need it or remains a wonder accessible only to the few.